Latest Asx News

Ovanti Limited is proposing to issue over 520 million free-attaching options to recent placement investors and its lead manager, exercisable at $0.025 and expiring in 2030, pending shareholder approval.

Strata Minerals’ Phase 2 drilling at Zelica confirms consistent shallow high-grade gold over a 1km strike, revealing new plunging shoots and a hanging-wall lode that could expand the system across a 9.5km corridor.

Electro Optic Systems (ASX:EOS) has raised A$190 million through institutional and strategic placements at an 9.3% discount, alongside a planned A$25 million share purchase plan, to fund its MARSS acquisition and expand defence capabilities.

RAS Technology Holdings has locked in new contracts and extensions expected to add at least $2 million in annualised revenue, reinforcing growth in wagering technology and international markets.

MyEco Group has extended its partnership with Penrith City Council by winning a 3-to-5-year contract to supply compostable caddy liners for the council's FOGO program, aligning with NSW's mandated organics recycling rollout.

Mach7 Technologies has secured a five-year, A$1.7 million subscription contract with US teleradiology provider AMRADNET, slashing deployment time from 12 months to just 45 days.

FIN Resources has bolstered confidence in its Cabin Lake gold system with new high-grade assay results from shallow drilling at the Arrow Prospect, underpinned by integrated geophysical data that sharpens exploration focus.

Strategic Elements Limited is raising up to $1 million via a Share Purchase Plan (SPP) at 3.5 cents per share, with attaching options exercisable at 4 cents, to fuel development in Energy Ink™ and Stealth Technologies.

Ex-CEO Geoff Cockerill has initiated court proceedings against Vitura Limited, alleging breaches of the Fair Work Act related to his January 2026 departure. Vitura maintains all contractual obligations were met and plans to resolve the dispute swiftly.

Close the Loop Limited has sold its ISP Tek Services business for US$10 million, slashed US$16 million of debt, and set an optimistic EBITDA target of $14 million to $16 million for FY27, signalling a sharper focus on its packaging and resource recovery strengths.

Patrys has appointed CMAX and Alithia Life Sciences to lead its Phase 1A clinical trial operations for RLS-2202, advancing its injectable quetiapine program toward first-in-human testing in Q3 2026, pending ethics approval.

Thrive Tribe Technologies (ASX:1TT) is issuing approximately 116.87 million Loyalty Options to shareholders at no cost, exercisable at $0.003 each and expiring in 2029, aiming to reward loyalty and potentially raise capital upon exercise.